News
NVO
44.89
-0.94%
-0.43
Novo Nordisk downgraded to Hold from Buy at Berenberg
TipRanks · 13h ago
Weekly Report: what happened at NVO last week (0810-0814)?
Weekly Report · 14h ago
Novo, LightPath, Jasper, UMAC, CCEP Trending With Analysts
TipRanks · 2d ago
Eli Lilly Just Scored Europe's First Weight Loss Pill Approval -- and the Growth Story Keeps Getting Bigger
The Motley Fool · 3d ago
Inside ARMH, STHH and ASMH: Three Semiconductor ADRhedged™ ETFs, and What the Currency Hedge Actually Added
TipRanks · 3d ago
Novo Nordisk (NVO) Sues A Rival Over Obesity Drug Advertising Claims
Simply Wall St · 3d ago
WST Q2 Beat and Raised 2026 Outlook Reinforce the HVP Growth Story
NASDAQ · 4d ago
Should Investors Buy WST as HVP Growth Meets a Premium Valuation?
NASDAQ · 4d ago
Is Novo Nordisk's Wegovy-Fueled Rebound Evaporating?
The Motley Fool · 4d ago
Novo Nordisk Completes Key Oral Semaglutide Study in Japan: What Investors Should Watch
TipRanks · 4d ago
Novo Nordisk’s SEMA-CardioDiab Hungary Study: What Real-World Oral Semaglutide Data Could Mean for NVO Investors
TipRanks · 4d ago
Novo Nordisk CEO Doustdar says obesity drugs market won't be dominated by one player
Seeking Alpha · 4d ago
Novo Nordisk CEO Defends Lawsuit Against Eli Lilly (LLY)
TipRanks · 4d ago
Novo Nordisk Stock (NVO) Falls as CEO Weighs In on Obesity Drug Rivalry with Eli Lilly
TipRanks · 4d ago
Novo Nordisk (NVO) Stock Still Looks Cheap On Earnings But Faces Growth Doubts
Simply Wall St · 5d ago
I Underestimated Eli Lilly: Retatrutide Changes The Risk/Reward (Rating Upgrade)
Seeking Alpha · 5d ago
The Market Is (Still) Underestimating Novo Nordisk
Seeking Alpha · 5d ago
Hims & Hers’ Revenue Beat Came With a Profitability Problem
NASDAQ · 5d ago
Eli Lilly is suing pharmacies and peptide vendors over sale of its next big weight-loss drug: retatrutide
MarketWatch · 5d ago
Novo Nordisk (NVO) Receives a Hold from BMO Capital
TipRanks · 5d ago
More
Webull provides a variety of real-time NVO stock news. You can receive the latest news about Novo-Nordisk A/S through multiple platforms. This information may help you make smarter investment decisions.
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.